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House dust mite avoidance measures improve 
peak flow and symptoms in patients with 
allergy but without asthma: A possible delay in 
the manifestation of clinical asthma?
S. G. M. Cloosterman, MSc,a I. D. Hofland, MSc,a H. G. M. Lukassen, MSc,a 
M. H. Wieringa, MSc,a H. Th. M. Folgerung, MD, PhD,b S. van der Heide, MSc,c 
B. Brunekreef, PhD,d and C. P. van Schayck, MSc, PhD0
Nijmegen, Groningen, and Wcigeningen, The Netherlands
Background: Asthma caused by allergy to house dust mite is 
a growing problem. Patients with allergy who do not have 
asthma (yet) might develop asthma depending on exposure 
to precipitating factors.
Objective: We sought to determine whether house dust mite 
avoidance measures have an effect on the development of 
asthma.
Methods: Patients with allergy {n =  29) who had no diagnosis 
of asthma (FEV1 of 99.1% ±  10.6% of predicted, peak flow vari­
ability of 5.21% ±  3.41%, reversibility of FEV1 after 400 jxg sal- 
butainol of 3.92% ± 3.75% according to the reference values) 
were randomly allocated (subjects blinded) to a treatment (n =  
16) and a placebo group (n = 13). House dust mite avoidance 
treatment consisted of applying Acarosan (AJlergopharma,
J, Ganzer KG, Hamburg, Germany) (the placebo group used 
water) to the floors (living room, bedroom), and the use of cov­
ers for mattresses and bedding that were impermeable to house 
dust mite (the placebo group used cotton covers for mattresses 
only). We tested whether the intervention had an effect on peak 
flow parameters and asthma symptom scores during 6 weeks of 
treatment.
Results: Significant improvements were seen in the treatment 
group in symptom scores (Borg score) for disturbed sleep, 
breathlessness, wheeze, and overall symptom score. Slight 
but statistically significant improvements in peak flow 
(morning, evening, and variability) were seen in the treat­
ment group also. No significant changes were seen in the pla­
cebo group.
Conclusions: Although this study is not long enough to study 
the development of asthma, the results indicates that house 
dust mite avoidance measures had an effect on peak flow pa^  
raineters and asthma symptoms in patients with allergy but 
without asthma. These findings might implicate that a shift 
in developing clinically manifest asthma could be achieved
From the “Department of General Practice and Social Medicine and 
•'Department o f  Pulmonary Diseases, Medical Centre Dekkerswald, 
University of Nijmegen, the d e p a r tm e n t  of Allergy, University of 
Groningen, and the ^Department of Epidemiology and Public Health, 
University of Wageningen.
Supported by the Dutch Asthma Foundation, by CIBA, and by 3M 
Pharma Industries.
Received for publication Dec. 18,1996; revised April 17, 1997; accepted 
for publication April 21, 1997.
Reprint requests: Dr. S.G.M. Cloosterman, D epartm ent o f  General 
Practice and Social Medicine, 229, University of Nijmegen, P.O. Box 
9101, 6500 HB Nijmegen, The Netherlands.
Copyright © 1997 by Mosby-Year Book, Inc.
0091-6749/97 $5.00 +  0 1/1/82994
with house dust mite avoidance measures. To give a better 
answer to whether preventing the development of asthma is 
possible, larger studies with a longer follow-up period are 
necessary. (J Allergy Clin Immunol 1997;100:313-9.)
Key words: House dust mite, allergen avoidance, peak flow, 
asthma symptoms, prevention
Asthma caused by allergy to house dust mite seems to 
be a growing problem in the western world .1 In the 
Netherlands, about 21 .8% of subjects 20 to 44 years old 
are allergic to the house dust mite and about 7%  of these 
have asthma.2 Considerable epidemiological evidence 
indicates a (causal) relationship between the level of 
exposure to house dust mite allergens and the risk of 
asthma .3'8 These findings implicate that in some sub­
jects, being allergic may be an expression of a possible 
genetic disposition for the development of asthma. 
Hence, subclinical asthma might become clinically man­
ifest asthma after exposure to allergens or other precip­
itating factors. Obviously, this presumption emphasizes 
the need for allergen avoidance protocols as a tool for 
prevention.8' 10 The treatment of asthma in adults should 
be focused on treating the disease as well as on prevent­
ing further development of the disease by avoiding 
allergens in patients with subclinical asthma . 11 Allergens 
of house dust mites are some of the most important 
triggers for the manifestation from allergy to asth­
ma.6, I2,13 Therefore, we investigated the effect of reduc­
ing house dust mite allergen exposure on the manifes­
tation of asthma in subjects who have an allergy to the 
house dust mite, but who do not (yet) have asthma.
Several studies investigated the effect of avoidance 
measures to reduce exposure to dust mite allergens in 
patients with already established asthma. Avoidance 
measures included tannic acid, acaricides, and covers for 
bedding. Most of these products have been shown to be 
capable of reducing the level of exposure to house dust 
mite allergen to a certain degree .14' 19 Data also indicate 
that a combination of measures gives a more pro­
nounced result in reducing exposure to these aller­
gens.1, :!6,20-23 Furthermore, several studies found a fa­
vorable influence on clinical parameters as a result of 
these measures. 1,20,21 So far, all of these measures have
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TABLE I. Characteristics of the study population
Treatment Placebo P
Population characteristics group group Value
Number 16 13
Gender (% male) 38 46 0.93
Age (yr) 32.4 (11.5) 23.5 (6.3) 0.04
Morning peak flow (L/min) 488.9 (109.4) 500.1 (85.2) 0.77
Evening peak flow (L/min) 508.1 (102.4) 511.2(84.2) 0,93
Peak flow variability (% ) 6.2 (4.0) 3.9 (2.1) 0.06
Asthma symptom scores: *
Breathlessness 1.19(1.3) 0.48 (0.7) 0.09
Disturbed sleep 0.73 (1.2) 0.37 (0.5) 0.28
Wheeze 0.60(1.2) 0.26 (0.5) 0.31
Overall symptom score 1.88 (1.2) 1.49 (1.3) 0.40
(square root)
Reversibility (% of 4.84 (3.86) 2.78 (3.42) 0.14
baseline)
FEV1 %  predicted 99.1 (9.5) 99.1 (12.2) 0.99
Allergy to:
Pets (%) 56.2 53.8 1.00
Pollen (%) 50.0 46.2 1.00
Potential confounders;
Textile bedroom 68.7 61.5 0.99
covering (% )
Smoking behavior (%) 25.0 23.1 1.00
Pets (%) 62.5 76.9 0.67
Data reported as mean ± SD. 
*Borg score.
been aimed at patients who have already developed 
asthma,16,24 and no attention has been paid to the 
preventive effect of these products on the development 
from allergy to asthma in patients with allergy.
Because investigation of the manifestation from sub- 
clinical to clinical asthma would need very long-term, 
large studies, we first performed a trial to assess what 
kind of effects house dust mite avoidance measures have 
in a group of adult patients with allergy during a 
relatively short follow-up period of 6 weeks. In none of 
the selected patients had asthma been diagnosed. Pa­
tients were specifically excluded if they had been diag­
nosed as having asthma or if they used inhaled cortico­
steroids or cromones. The house dust mite reducing 
measures used in this study were the combination of 
solidified benzyl benzoate (Acarosan, Allergopharma, 
J. Ganzer KG, Hamburg, Germany) for the living room 
and bedroom floor (the group receiving placebo used 
water) and the encasement of mattress, duvet, and 
pillows with house dust mite-impermeable covers (Al­
lergy Control; MediTex, Rossum, The Netherlands) (the 
group receiving placebo used mite-permeable covers for 
mattresses only). We assessed what kind of effect these 
house dust mite reducing measures had on peak flow 
parameters and on asthma symptom scores»
METHODS 
Patients
Patient characteristics are given in Table I. Patients were 
recruited after their general practitioners referred them to the
hospital for intradermal skin testing. All patients had an allergy 
test because they had some very mild signs of asthma (mostly 
early morning dyspnea or wheeze), but none had a diagnosis of 
asthma. After this test, patients remained under the medical 
care of the general practitioner and not of a specialist. Patients 
were excluded if they had a confirmed diagnosis of asthma, if 
they had received anti-inflammatory medication at any time, or 
if they had an increased peak flow variability (>15% ) or a 
reversibility of the obstruction (>15%  of predicted FEV1 after 
400 fig salbutamol). According to the recent World Health 
Organization/National Institutes of Health consensus, these 
patients are not defined as having asthma (even mild asthma).25 
This study focused only on asthmatic and not on nasal symp­
toms; rhinitic complaints were not an exclusion criterion and no 
data about nasal symptoms were collected.
Patients were selected from intradermal skin test records 
during 1991 and 1992, All patients were tested for 16 common 
aeroallergens (pollen, pets, molds, and house dust mite; ALK, 
Assen, The Netherlands). Histamine served as a positive con­
trol and a solution without a specific allergen served as a 
negative control. A  reaction was defined as positive when the 
reaction (wheal size) to an allergen was 5^0.7 times the reaction 
(wheal size) of the positive control. Wheal size was calculated 
by multiplying the longest length with the perpendicular width 
and this total was divided by two. All patients had a positive 
intradermal allergy test for house dust mite. T he  reaction to 
cats, dogs, and Aspei-gillus fiimigatus had to be less than the 
reaction to house dust mite to avoid interference with these 
allergens. Furthermore, patients with an allergy to pollen were 
equally distributed over the two groups.
Design
This study was a prospective, single-blind, placebo-controlled 
trial, which started with a baseline period of 2 weeks followed 
by an intervention period of 6 weeks. The study took place in 
the spring of 1993. Patients were entered into the study 
concurrently and after the baseline period they were randomly 
allocated to the allergen avoidance group or to the placebo 
group. Allocation was done after stratification based on the 
type of floor covering in the bedroom (textile versus smooth) 
and on the initial FEV1 (%  reference value). Patients were 
unaware of their allocation to the treatm ent group or the 
placebo group (single-blind). All patients were asked to clean 
the floors of their living room and bedroom with a vacuum 
cleaner and to wash the bedding once a week to standardize the 
cleaning conditions of the indoor environment.
During the following 6 weeks, we assessed whether the 
allergen avoidance measures had an effect on asthma symptoms 
and peak flow parameters.
Mite avoidance measures (treatment group)
In the treatment group (n -  16), the acaricide benzyl 
benzoate moist powder Acarosan was applied to the bedroom 
and living room coverings according to a standard procedure. It 
was brushed in firmly after the removal of furniture from the 
floor and was removed by intensive vacuuming 3 hours after 
application. Mattresses, pillows, and duvet w ere all encased 
with covers (Allergy Control) that are impermeable to house 
dust mites and house dust mite allergens. W e have shown 
earlier that these active covers are quite effective.26
Placebo measures (placebo group)
In the placebo group (n = 13), textile bedroom and living 
room floor coverings were sprayed lightly with water from a
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siphon with a label of an acaracide, after the furniture was 
removed from the floor. After 15 minutes the floors of the 
bedroom and living room were vacuumed. For mattresses, 
placebo covers permeable for the house dust mite were used. 
Patients were given the impression that these measures were 
part of the active avoidance measures,
Clinical features
Patients were provided with peak flow meters (Pocket Peak 
Flow Meter, Micro Medical, Rochester, Kent) and were trained 
in recording three readings each morning before breakfast and 
each evening before dinner. The highest of the three (both in 
the morning and the evening) were recorded. Patients also 
scored symptoms of cough, breathlessness, wheezing, expecto­
ration, tiredness, and disturbed sleep (due to cough, wheeze, or 
breathlessness at night) on a modified Borg scale (0 =  no 
symptoms to 10 = severe symptoms).27 The peak flow values 
and symptom scores were recorded daily on a diary card during 
the study. Before the start of the study, patients were trained to 
measure and record their peak flow and symptoms. During the 
2-week baseline, the diary cards were also filled in to obtain 
initial values of all parameters. To avoid learning effects, only 
the data from the second week were taken for the baseline 
period.
During the first home visit, information about the bronchial 
symptoms, smoking habits, occupation, and frequency of house 
cleaning was obtained by a questionnaire.
Statistical analyses
Sample sizes were estimated based on peak flow morning 
values with an a  of 0.05 and a p of 0.80. The minimal clinical 
relevant difference to be detected was set at 15 L/min (with a 
standard deviation of 15 L/min),28 because no asthma had been 
diagnosed and consequently little room for improvement was 
possible. Sample sizes were estimated at 15 patients per group. 
All p  values were assessed with two-sided tests.
Values for morning and evening peak flow, peak flow vari­
ability, measured as ([highest peak flow -  lowest peak flow])/ 
[highest peak flow] X 100), and asthma symptom scores were 
calculated as means during 1 week before intervention and for 
each consecutive week after intervention. Changes between 
each week of follow-up and baseline were calculated for all 
parameters, resulting in mean changes (±  standard error). An 
overall symptom score was calculated by adding up the separate 
symptom scores for each mean of the week followed by square 
root transformation to achieve a normal distribution.
Within-group comparisons were made by testing differences 
after 1, 2, 3, 4, 5, and 6 weeks with the baseline value for all 
parameters by Student’s paired t test. A cross-sectional com­
parison of the changes compared with baseline between the two 
groups was made by means of the Student unpaired t test. When 
baseline values differed (p <  0.10), a correction for baseline 
values was made by MANOVA. Drop-outs were included in the 
analyses as far as they completed the study (intention to treat 
protocol). An explanatory analysis was also done with only 
patients who completed the study.
RESULTS
Patient characteristics
Twenty-nine patients were included in the study. After 
randomization and stratification, a slightly unbalanced 
distribution was achieved, with 16 patients in the treat­
ment group and 13 patients in the placebo group. Patient 
characteristics are shown in Table I. Only age differed
significantly between the groups, in that the treatment 
group was older than the placebo group (31 vs 24 years). 
In all analyses, the difference in age had no influence on 
any of the effects studied (p values always >0.05). All 
parameters studied were normally distributed.
Only a few patients used pulmonary medications: five 
patients used a (3-agonist on demand (three in the 
treatment group and two in the placebo group), and five 
patients used antihistaminics (three in the treatment 
group and two in the placebo group).
In both groups some patients dropped out, As base­
line values of peak flow parameters and asthma symp­
tom scores of the dropouts and those who completed the 
study were not different, the act of droping out appeared 
not to be selective. The treatment group started with 16 
patients. During weeks 1,2, and 3 no dropouts occurred, 
in week 4 one patient dropped out, and in week 5 one 
also dropped out. Three patients dropped out in week 6, 
so the treatment group ended with 11 patients. The 
placebo group started with 13 Patients. During the first
3 weeks no dropouts occurred, In week 4 three patients 
dropped out and in week 5 two patients dropped out. In 
week 6 the placebo group ended with 7 patients. Patients 
left the study because of motivational factors not related 
to the study objective, and factors did not differ signifi­
cantly between the two groups. Furthermore, the explan­
atory analyses showed no real differences compared with 
the intention to treat analyses.
Peak flow morning values and peak flow 
variability
Fig. 1 shows the changes in the weekly mean values 
compared with the pretreatment week for peak flow 
morning values, peak flow evening values, and peak flow 
variability.
Improvements in peak flow parameters were seen only 
in the treatment group. Peak flow morning values 
showed significant increases from +13.2 ± 5.4 L/min 
in week 4 (p = 0.029) to +18.2 ± 6.9 L/min in week 6 
(p = 0.030), Peak flow evening values also showed 
an increase. This increase became significant in week
4 (+8.53 ± 3.4 L/min, p = 0.027), which tended to 
continue in weeks 5 and 6 (+8.57 ± 4.3 L/min [p = 
0.070] and +21,89 ± 9.7 L/min [p =  0.054], respectively). 
Peak flow variability showed no statistically significant 
differences, although it tended to decrease in week 3 
(-1.36% ±  0 ,7 %, p  =  0.080) up through week 6 (-2.18%
± 1.0%,/? -  0.064).
Asthma symptom scores
The treatment group showed an improvement in the 
symptom scores for disturbed sleep, breathlessness, 
wheeze, and the overall symptom score (Fig, 2),
Patients in the treatment group had less disturbed 
sleep in week 4 ( —0.52 ± 0.3 on the Borg score, p = 
0.063) and week 5 (-0 .45 ± 0.2 on the Borg score,/? =
0.050). In the placebo group, no significant changes in
disturbed sleep were seen.
The symptom score for breathlessness tended to de­
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FIG. 1. Mean ± SEM changes in peak flow morning values {A), peak flow evening values (B), and peak flow  
variability (C) compared with baseline for the treatment group (■) and the placebo group (A). A, Significant 
increases in peak flow  morning values compared with baseline occurred only in the treatment group during 
w eeks4(*p  = 0.029), 5 {#p -  0.024), and 6 ($p = 0.030), B, In the treatment group, a significant increase in peak 
flow evening values compared with baseline was also seen during week 4 (* p  -  0.027). This tendency was also 
seen during weeks 5 (#p = 0.070) and 6 ($p = 0.054). C, Peak flow variability tended to decrease in the 
treatment group. This tendency was most pronounced in week 6 (*p = 0.064).
crease in the treatment group. This tendency became 
significant in. week 5 (-0.47 ±  0,19 on the Borg score, 
p ~  0.024) and week 6 (-0.84 ± 0.3 on the Borg score, 
p  =  0 .020).
An improvement was also seen for the symptom score 
for wheeze in the treatment group; it was significant in 
week 5 (-0.31 ± 0.1 on the Borg score,/? = 0.032). The 
decrease in Borg score in the treatment group in week 5 
differed significantly from the increase in the placebo 
group in week 5 (change was 0,53 ± 0.24 on the Borg 
score,/? = 0.038).
The overall score (square root) decreased in weeks 4,
5, and 6 . These decreases were -0.41 ± 0.2 (p = 0.039), 
-0.54 ± 0 .2  (p = 0.005), and -1.02 ± 0 .2  (p = 0.002),
respectively.
DISCUSSION
Sufficient evidence has accumulated to confirm a close 
relation between sensitivity to mite allergens and asth­
m a .7»29,30 A causal relationship between mite allergen 
sensitization and the development of asthma seems 
plausible.3^ 8,31 Consequently, in some patients allergy 
might be an indication of a genetic disposition for 
asthma; in other words, allergy might be considered in
thevSe patients as a subclinical (early) expression of 
asthma. Therefore, in these patients, preventing further 
development from subclinical to clinical asthma by re­
ducing the exposure to allergens is important. Because 
house dust mite allergens are one of the most important 
allergens in asthma, preventive measures should be 
especially focused on avoidance of these allergens. The 
prevention of asthma is difficult to study, because the 
assessment of the development of asthma would need a 
very long-term observation of objective variables in 
controlled circumstances. Because of the relatively short 
follow-up period and small number of patients, this 
short-term study can only serve as a preliminary report 
in investigating possibilities of preventing the develop­
ment of asthma.
This study showed that after 6 weeks of follow-up, 
small but significant improvements were seen in asthma 
symptoms (disturbed sleep, breathlessness, wheeze, and 
overall symptom score) and peak flow parameters in the 
patients who received a combination of measures to 
avoid house dust mites. Unfortunately, the actual aller­
gen load was not measured to objectify the effectiveness 
of the intervention. Nevertheless, we believe that the 
intervention used has been effective and was not, for
j  ALLERGY CLIN IMMUNOL
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A. Disturbed sleep
B. Breathlessness
C. Wheeze D. Overall symplom score
FIG. 2. Mean ± SEM changes in the symptom scores for disturbed sleep (A), breathlessness (B), wheeze (C), 
and overall symptom score (square root) (D) compared with baseline for the treatment group {■) and the 
placebo group (A). A, A tendency toward a decrease in Borg score for disturbed sleep was seen in the 
treatment group during week 4 {*p = 0.063), which became significant in week 5 (#p = 0.050). B, Significant 
differences for breathlessness compared with baseline were seen only in the treatment group during weeks
5 (*p ~ 0.024) and 6 (#p = 0,020). C, A significant decrease in wheeze was seen in the treatment group during 
week 5 (*p = 0.032). This decrease in the treatment group was significantly different from the increase in the 
placebo group (p = 0.038). This tendency was also seen in week 6 (#p = 0.077). D, Significant decreases in 
overall symptom score (square root) with baseline occurred only in the treatment group during weeks 4 (*p =
0.039), 5 (#p = 0.005), and 6 ($p = 0.002).
example, a consequence of seasonal variation in house 
dust mite levels (because patients in the treatment and 
placebo groups undertook the study at the same time). 
In particular, the mite-impermeable covers are thought 
to be largely responsible for a reduction in house dust 
mite allergens, and reduction was achieved to a lesser 
extent with the use of Acarosan.9,32,33 It could be 
possible that especially in this group of patients who had 
not yet developed asthma, the proposed intervention 
might be relatively effective. In a group of patients with 
already clinically manifest asthma, we would probably 
need a more powerful intervention.
The classification of the patients in this study is very 
important. It must be clear that these patients do not 
have a diagnosis of asthma, but rather they have no 
clinically manifest asthma. Our patients only had 
some complaints (mainly breathlessness, wheeze, and 
cough), but peak flow parameters were normal and 
patients used no anti-inflammatory medication. Fur­
thermore, FEV1 and reversibility of obstruction were 
also normal. Thus (reversible) airflow limitation 
seems to be absent in these patients. When peak flow
variability is seen as an indication of airway respon­
siveness, it may be assumed that airway responsive­
ness is absent in this group of patients. Unfortunately, 
bronchial hyper responsiveness was not measured in 
these patients.
The effects observed were very small, which can be 
explained by the fact that there was little room for 
improvement in these parameters because these patients 
did not have asthma but had only some (early) signs of 
subclinical asthma. Our results show that with the help 
of avoidance measures for house dust mite, peak flow 
variation and symptom scores can be stabilized or im­
proved during a 6-week period. This might implicate a 
shift in the moment when asthma manifests clinically. 
Obviously, we cannot predict from these results the 
extent of this shift in disease manifestation. Questions as 
to whether the manifestation of asthma will only be 
delayed, to what extent this delay will happen, or 
whether the manifestation might actually be prevented 
can only be answered by studies with a much longer 
follow-up period and with more patients. In this study, 
most effects increased toward the end of the 6-week
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period, which might indicate that a “plateau” in the 
maximum effect was not reached yet.
To our knowledge, this is the first study that gives 
more insight in the use of allergen avoidance as preven­
tive measures in adults who do not have asthma (yet). 
Evidence of a (causal) relationship between the level of 
exposure to house dust mite allergen and the risk of 
developing clinical asthma has been achieved in cross- 
sectional and retrospective studies.3' 10,29'31 No long­
term prospective studies in adults have been reported. 
Studies dealing with the prevention of asthma are usu­
ally performed in children.34'36 These studies try to 
prevent the sensitization to house dust mite allergens, 
and as such they are focused on primary prevention of 
asthma. However, many adult patients have an allergy 
but do not (yet) have asthma .2 A substantial number of 
these patients will present to their physicians with some 
mild, very early asthma-like symptoms. Usually patients 
with these kinds of symptoms are tested for the presence 
of (house dust mite) allergy. When allergy is present, 
preventing the further development of these symptoms 
toward clinical asthma might be a relevant option. 
Studies investigating this kind of prevention are urgently 
needed. Not only is it important to investigate whether 
prevention is efficacious, but it is also important to 
determine which (combination of) avoidance measures 
will yield the best result.
In conclusion, this study investigated the effects of 
house dust mite avoidance measures in a group of 
patients with allergy (subclinical asthma). The study was 
undertaken to gain more insight in the possible preven­
tive capacity of these measures. The study showed that 
after 6 weeks of follow-up, house dust mite avoidance in 
patients with allergy but without asthma improves peak 
flow parameters and asthma symptom scores. These 
findings might indicate that a shift in the development of 
clinical asthma is achievable with avoidance measures. 
These findings are not conclusive because of the rela­
tively short follow-up period and small number of pa­
tients. These findings can therefore only serve as an 
indication that early allergen avoidance might have a 
favorable effect on the development of asthma. To 
investigate this hypothesis, we urgently need longer 
follow-up studies with lager groups. In this way a better 
understanding of the preventive capacity of house dust 
mite avoidance measures in the development of asthma 
can be obtained.
We thank Mr. R. Akkermans for his statistical support. 
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